Kurt A. Jaeckle

Mayo Clinic in Florida — United States

Medicine · Health Sciences

66h-index19.3kcitations244works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(148), Brain Metastases and Treatment(74), Radiomics and Machine Learning in Medical Imaging(27), Cancer Treatment and Pharmacology(24), Cancer, Hypoxia, and Metabolism(21)

Publications237 total

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
2026Open Access
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025Open Access
Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025Open Access
CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Neuro-Oncology·2025Open Access
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
Clinical Cancer Research·2025· 1 cited
Data from Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas
2025Open Access
Supplementary Tables and Figures 1 from Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas
2025Open Access
Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas
Clinical Cancer Research·2025Open Access
BIOM-59. INDIVIDUALIZED TUMOR-SPECIFIC AMPLIFIED DNA JUNCTIONS FOR PLASMA-BASED MONITORING IN PATIENTS WITH HIGH-GRADE GLIOMAS
Neuro-Oncology·2024Open Access
BIOM-12. ALLIANCE A071401: GENOMICALLY GUIDED PHASE II TRIAL OF ABEMACICLIB IN PATIENTS WITH GRADE 2/3 MENINGIOMAS HARBORING SOMATIC NF2 OR CDK PATHWAY ALTERATIONS
Neuro-Oncology·2024· 1 citedOpen Access
CTNI-61. PRELIMINARY RESULTS OF A PHASE I/II TRIAL OF SELINEXOR AND TEMOZOLOMIDE IN RECURRENT GLIOBLASTOMA
Neuro-Oncology·2024Open Access
Efficacy of Adding Veliparib to Temozolomide for Patients With <i>MGMT</i>-Methylated Glioblastoma
JAMA Oncology·2024· 17 citedOpen Access
JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology·2024Open Access
Tumor Treating Fields Utilization for Glioblastoma at a Large Multicenter Academic Practice
International Journal of Radiation Oncology*Biology*Physics·2024· 1 cited
Modern Patterns of Failure for Glioblastoma at a Large Multicenter Academic Practice
International Journal of Radiation Oncology*Biology*Physics·2024
Clinical features and outcomes in primary nervous system histiocytic neoplasms
Blood Cancer Journal·2024· 2 citedOpen Access
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.
Journal of Clinical Oncology·2024· 3 cited
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Journal of Clinical Oncology·2024· 2 cited
Isolated Nervous System Histiocytic Neoplasms: Clinical Manifestations, Treatment, and Outcomes (P4-5.018)
Neurology·2024
Case Report: “Aggressive” perioperative antiseizure medication prophylaxis in patients with glioma-related epilepsy at high risk of early postoperative seizures following awake craniotomy
Frontiers in Surgery·2024· 2 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Evanthia Galanis(11), Jan C. Buckner(11), Paul D. Brown(10), David Schiff(9), Caterina Giannini(9), Karla V. Ballman(8), Minesh P. Mehta(7), Michael D. Prados(7), Martin J. van den Bent(7), Patrick Y. Wen(7), Patrick J. Flynn(7), Mark R. Gilbert(6), S. Keith Anderson(6), Marc C. Chamberlain(6), Terri S. Armstrong(5), Michael A. Vogelbaum(5), Victor A. Levin(5), Surasak Phuphanich(5), Jeffrey S. Wefel(4), Deborah T. Blumenthal(4)